Abstract Objective: To discuss the approach to patients diagnosed with growth hormone deficiency (GHD) in childhood during the transition period from puberty to adulthood, focusing on the following: (1) physiology; (2) effects of recombinant human GH (rhGH) interruption/reinstitution after adult height achievement; (3) re-evaluation of somatrotropic axis; (4) management of rhGH reinstitution, when necessary. Source of data: Narrative review of the literature published at PubMed/MEDLINE until September 2020 including original and review articles, systematic reviews and meta-analyses. Synthesis of data: Growth hormone is crucial for the attainment of normal growth and for adequate somatic development, which does not end concomitantly with linear growth. Retesting adolescents who already meet the criteria that predict adult GHD with high specificity is not necessary. Patients with isolated GHD have a high likelihood of normal response to GH testing after puberty. Adolescents with confirmed GHD upon retesting should restart rhGH replacement and be monitored according to IGF-I levels, clinical parameters, and complementary exams. Conclusion: Patients with isolated idiopathic GHD in childhood are a special group who must be reevaluated for GHD as many of them have normal GH provocative tests upon retesting after puberty. Patients who confirm the persistence of GHD in the transition period should maintain rhGH replacement in order to reach an ideal peak bone mass, satisfactory body composition, lipid and glucose profiles, and quality of life.

Relata-se que a disfunção tireoidiana induzida pela amiodarona afeta de 2 a 24% dos usuários. Embora seja fácil tratar o hipotireoidismo induzido pela amiodarona, o desenvolvimento da tireotoxicose leva a uma abordagem difícil na maioria dos casos. O objetivo deste estudo é descrever três casos diferentes de pacientes com tireotoxicose induzida por amiodarona e discutir os aspectos clínicos e laboratoriais, e as diferentes abordagens para esses casos. É essencial avaliar cuidadosamente os pacientes antes e durante o tratamento com amiodarona, tendo em vista que o diagnóstico e o tratamento imediato dessa condição são cruciais em pacientes com alto risco cardiovascular.

Amiodarone-induced thyroid dysfunction has been reported to affect 2-24% of users. Despite the easy management of amiodarone-induced hypothyroidism, the development of thyrotoxicosis leads to a difficult approach in most cases. The aim of this study is to describe three different cases of patients with amiodarone-induced thyrotoxicosis and discuss the clinical and laboratorial aspects, and the different approaches to them. It is essential to carefully evaluate patients before and during amiodarone therapy, since the prompt diagnosis and treatment of this condition is essential in patients with high cardiovascular risk.

Se relata que la disfunción tiroidea inducida por la amiodarona afecta de 2 a 24% de los usuarios. Aunque sea fácil tratar el hipotiroidismo inducido por la amiodarona, el desarrollo de la tirotoxicosis lleva a un abordaje difícil en la mayoría de los casos. El objetivo de este estudio es describir tres casos diferentes de pacientes con tirotoxicosis inducida por amiodarona y discutir los aspectos clínicos y de laboratorio, y los diferentes abordajes para esos casos. Es esencial evaluar cuidadosamente los pacientes antes y durante el tratamiento con amiodarona, teniendo en vista que el diagnóstico y el tratamiento inmediato de esa condición son cruciales en pacientes con alto riesgo cardiovascular.